Hypermethylation of the BRCA2 gene promoter and its co-hypermethylation with the BRCA1 gene promoter in patients with breast cancer.

IF 4.6 Q2 MATERIALS SCIENCE, BIOMATERIALS

ACS Applied Bio Materials Pub Date : 2024-01-01 DOI:10.3233/CBM-230458

Liliia Fishchuk, Zoia Rossokha, Olga Lobanova, Valeriy Cheshuk, Roman Vereshchako, Viktoriia Vershyhora, Nataliia Medvedieva, Olha Dubitskaa, Natalia Gorovenko

{"title":"Hypermethylation of the BRCA2 gene promoter and its co-hypermethylation with the BRCA1 gene promoter in patients with breast cancer.","authors":"Liliia Fishchuk, Zoia Rossokha, Olga Lobanova, Valeriy Cheshuk, Roman Vereshchako, Viktoriia Vershyhora, Nataliia Medvedieva, Olha Dubitskaa, Natalia Gorovenko","doi":"10.3233/CBM-230458","DOIUrl":null,"url":null,"abstract":"Background: The BRCA2 gene is an important tumour suppressor in breast cancer, and alterations in BRCA2 may lead to cancer progression. The aim of the study was to investigate the association of hypermethylation of the BRCA2 gene promoter and its co-hypermethylation with the BRCA1 gene promoter with the development and course of breast cancer in women.Methods: This study included 74 women with breast cancer (tumour tissue samples and peripheral blood) and 62 women without oncological pathology (peripheral blood) - control group.Results: Hypermethylation of the BRCA2 gene was significantly more frequently detected in the tumour tissue of women with breast cancer compared to their peripheral blood and peripheral blood of control subjects (p= 0.0006 and p= 0.00001, respectively). Hypermethylation of BRCA2 was more frequently detected in patients with breast cancer over the age of 50 and in patients with higher Ki67 expression levels (p= 0.045 and p= 0.045, respectively). There was a high frequency of unmethylated BRCA1 and BRCA2 gene combination in women of the control group compared to women with breast cancer, both in blood samples and tumour tissue samples (p= 0.014 and p= 0.00001, respectively).Conclusion: Our study confirms the hypothesis that BRCA2 hypermethylation plays an important role in the pathogenesis of breast cancer and the importance of assessing its co-hypermethylation with BRCA1 in predicting the course of the disease.","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11380246/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3233/CBM-230458","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The BRCA2 gene is an important tumour suppressor in breast cancer, and alterations in BRCA2 may lead to cancer progression. The aim of the study was to investigate the association of hypermethylation of the BRCA2 gene promoter and its co-hypermethylation with the BRCA1 gene promoter with the development and course of breast cancer in women.

Methods: This study included 74 women with breast cancer (tumour tissue samples and peripheral blood) and 62 women without oncological pathology (peripheral blood) - control group.

Results: Hypermethylation of the BRCA2 gene was significantly more frequently detected in the tumour tissue of women with breast cancer compared to their peripheral blood and peripheral blood of control subjects (p= 0.0006 and p= 0.00001, respectively). Hypermethylation of BRCA2 was more frequently detected in patients with breast cancer over the age of 50 and in patients with higher Ki67 expression levels (p= 0.045 and p= 0.045, respectively). There was a high frequency of unmethylated BRCA1 and BRCA2 gene combination in women of the control group compared to women with breast cancer, both in blood samples and tumour tissue samples (p= 0.014 and p= 0.00001, respectively).

Conclusion: Our study confirms the hypothesis that BRCA2 hypermethylation plays an important role in the pathogenesis of breast cancer and the importance of assessing its co-hypermethylation with BRCA1 in predicting the course of the disease.

查看原文本刊更多论文

乳腺癌患者 BRCA2 基因启动子的超甲基化及其与 BRCA1 基因启动子的共超甲基化。

背景：BRCA2 基因是乳腺癌中重要的肿瘤抑制因子，BRCA2 基因的改变可能导致癌症进展。本研究旨在探讨 BRCA2 基因启动子的高甲基化及其与 BRCA1 基因启动子的共超甲基化与女性乳腺癌的发生和发展的关系：研究对象包括74名乳腺癌妇女（肿瘤组织样本和外周血）和62名无肿瘤病理（外周血）的妇女--对照组：结果：与外周血和对照组的外周血相比，在乳腺癌妇女的肿瘤组织中检测到 BRCA2 基因的高甲基化频率明显更高（分别为 p= 0.0006 和 p= 0.00001）。在 50 岁以上的乳腺癌患者和 Ki67 表达水平较高的患者中，更常检测到 BRCA2 的高甲基化（分别为 p= 0.045 和 p=0.045）。与乳腺癌妇女相比，对照组妇女血液样本和肿瘤组织样本中未甲基化的 BRCA1 和 BRCA2 基因组合的频率较高（分别为 p= 0.014 和 p= 0.00001）：我们的研究证实了 BRCA2 高甲基化在乳腺癌发病机制中扮演重要角色的假设，以及评估 BRCA2 与 BRCA1 共同高甲基化在预测疾病进程中的重要性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ACS Applied Bio Materials Chemistry-Chemistry (all)

CiteScore

9.40

自引率

2.10%

发文量

464